Healthcare
Live Price
Offline$46.90
-0.21% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Dechra Pharmaceuticals PLC (DCHPF) is a Healthcare stock with a market cap of $5.34B. The stock last traded around $46.90. Baseline metrics include revenue growth of +11.7%, EPS growth of -144.4%, a dividend yield of 0.3%. What stands out right now is revenue +11.7%, EPS -144.4%, free cash flow -26.5% with operating margin 0.8% and ROIC 0.3%. The dividend is present but secondary, with a yield around 0.3%. Valuation sits in the middle of the pack at price/sales 5.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DCHPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
DCHPF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
DCHPF Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for DCHPF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$481.8M
-6.5% YoY
FY Net Income
$30.9M
-8.8% YoY
Free Cash Flow
$59.3M
+3.7% YoY
Revenue Growth
+11.7%
EPS Growth
-144.4%
Gross Margin
56.0%
Net Margin
-3.7%
Income statement
GBP
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 762M | 682M | 608M | 515M | 482M |
| Gross Profit | 426M | 385M | 346M | 292M | 273M |
| Operating Income | 6M | 96M | 84M | 52M | 39M |
| EBITDA | 87M | 179M | 162M | 131M | 123M |
| Net Income | -28M | 58M | 56M | 34M | 31M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
GBP
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 74M | 121M | 118M | 227M | 80M |
| Total Assets | 1.6B | 1.3B | 1.2B | 1.2B | 1.0B |
| Total Liabilities | 814M | 627M | 581M | 600M | 539M |
| Shareholder Equity | 755M | 667M | 633M | 638M | 509M |
| Total Debt | 505M | 329M | 319M | 355M | 308M |
| Net Debt | 430M | 208M | 200M | 128M | 228M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
82M
-23.1% YoY
Capital Expenditures
23M
+54.3% YoY
Free Cash Flow
59M
+3.7% YoY
Key ratios
Gross Margin
56.0%
Operating Margin
0.8%
Net Margin
-3.7%
ROE
-3.9%
Debt / Equity
0.67x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.